Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Dyadic (company)

Dyadic (company)

Biotechnology company focused on development and production of biologic vaccines, drugs and other biologic products using its C1 microorganism expression platform

Dyadic is a global biotechnology company focused on applying its proprietary gene expression platform to accelerate development, lower production costs and improve performance of biologic vaccines, drugs and other biologic products. The biopharmaceutical gene expression platform is based on the C1 strain of the fungus Myceliophthora thermophila. The microorganism enables the development and large-scale manufacture of low-cost proteins, with the potential to be further developed into a safe and efficient expression system with applications in the production of biologic vaccines and drugs at flexible commercial scales. Dyadic uses their C1 technology for development of human and animal vaccines and drugs such as virus like particles (VLPs), antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters and other therapeutic proteins. Dyadic is also using their technology in development and manufacturing of Adenol-associated viral vectors (AAV) and certain metabolites.

Dyadic is collaborating with the Israel Institute for Biological Research (IIBR) on a treatment and a vaccine against COVID-19. IIBR are using Dyadic’s C1 gene expression platform to produce vaccine candidates and monoclonal antibodies to potentially prevent or treat COVID-19.

Timeline

Patents

Further Resources

Title
Author
Link
Type
Date

References

Golden logo
By using this site, you agree to our Terms & Conditions.